Anti-leukotrienes coverage coming

The Food and Drug Administration in December approved the second anti-leukotriene drug, zileuton, for the treatment of asthma. The FDA approved the first, zafirlukast, in September. These drugs represent an important new class of asthma medications. Look for comprehensive coverage of this emerging drug protocol in the April issue of Disease State Management. — The Editors